Journal of Endocrinological Investigation

, Volume 42, Issue 1, pp 75–83 | Cite as

Elevation of isoprostanes in polycystic ovary syndrome and its relationship with cardiovascular risk factors

  • M. CalzadaEmail author
  • N. López
  • J. A. Noguera
  • J. Mendiola
  • A. M. Torres
Original Article



To evaluate the plasma level of 8-isoprostanes in women with polycystic ovary syndrome. To also investigate whether there is a relationship between 8-isoprostanes and several cardiovascular risk factors.


A total of 125 women with polycystic ovary syndrome and 169 healthy women were enrolled in this case–control study. 8-Isoprostanes and different parameters were measured in all subjects. Patients were evaluated for the presence of polycystic ovary syndrome according to the Rotterdam Consensus Conference criteria.


8-Isoprostanes levels were significantly higher in patients with polycystic ovary syndrome (138.4 ± 104.1 pg/mL) compared with control group (68.6 ± 34.3 pg/mL) (p < 0.001). The mean of triglycerides, lipid accumulation product, C-reactive protein, homocysteine, insulin, and homeostatic model assessment for insulin resistance were significantly higher in polycystic ovary syndrome patients with high 8-isoprostanes than those with normal 8-isoprostanes (p < 0.05). The Pearson correlation analyses showed that 8-isoprostanes levels in polycystic ovary syndrome group had a positive correlation with waist circumference, triglycerides, low-density lipoprotein cholesterol, apolipoprotein B, homocysteine, insulin, homeostatic model assessment for insulin resistance.


Patients with polycystic ovary syndrome have higher 8-isoprostanes levels and it is associated with several cardiovascular risk factors.


Polycystic ovary syndrome Insulin resistance Oxidative stress 8-Isoprostanes Infertility 



The authors thank all the women for participating in this study. We also thank the nursing staff for their help.


This work was supported by a grant from the Institute of Health Carlos III (ISCIII) (no PI13/01237).

Compliance with ethical standards

Conflict of interest

The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Ethical approval

The authors declared that the manuscript has not been submitted to more than one journal for simultaneous consideration and it has not been published previously. No data have been fabricated or manipulated to support your conclusions. No data, text, or theories by others are presented as if they were the author’s own. This study is not split up into several parts to increase the quantity of submissions and submitted to various journals or to one journal over time. Consent to submit has been received explicitly from all co-authors, as well as from the hospital where the work has been carried out. All authors have contributed sufficiently to the scientific work and therefore share collective responsibility and accountability for the results.

Informed consent

In this controlled study participants were voluntarily recruited and they all signed an informed consent.


  1. 1.
    Norman RJ, Dewailly D, Legro RS, Hickey TE (2007) Polycystic ovary syndrome. Lancet 370(9588):685–697CrossRefGoogle Scholar
  2. 2.
    Padmanabhan V (2009) Polycystic ovary syndrome—”a riddle wrapped in a mystery inside an enigma”. J Clin Endocrinol Metab 94(6):1883–1885CrossRefGoogle Scholar
  3. 3.
    Franks S (1995) Polycystic ovary syndrome. N Engl J Med 333(13):853–861CrossRefGoogle Scholar
  4. 4.
    March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ (2010) The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 25(2):544–551CrossRefGoogle Scholar
  5. 5.
    Boudreaux MY, Talbott EO, Kip KE, Brooks MM, Witchel SF (2006) Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up. Curr Diab Rep 6(1):77–83CrossRefGoogle Scholar
  6. 6.
    Moran LJ, Misso ML, Wild RA, Norman RJ (2010) Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 16(4):347–363CrossRefGoogle Scholar
  7. 7.
    Cascella T, Palomba S, De Sio I, Manguso F, Giallauria F, De Simone B et al (2008) Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod 23(1):153–159CrossRefGoogle Scholar
  8. 8.
    Carmina E, Orio F, Palomba S, Longo RA, Cascella T, Colao A et al (2006) Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 119(4):356 e1–6CrossRefGoogle Scholar
  9. 9.
    Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF (2007) Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum Reprod 22(12):3197–3203CrossRefGoogle Scholar
  10. 10.
    Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF 2nd, Fitzpatrick LA (2003) Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88(6):2562–2568CrossRefGoogle Scholar
  11. 11.
    Basu S (2008) F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid Redox Signal 10(8):1405–1434CrossRefGoogle Scholar
  12. 12.
    Davies SS, Roberts LJ 2nd (2011) F2-isoprostanes as an indicator and risk factor for coronary heart disease. Free Radic Biol Med 50(5):559–566CrossRefGoogle Scholar
  13. 13.
    Stephens JW, Khanolkar MP, Bain SC (2009) The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease. Atherosclerosis. 202(2):321–329CrossRefGoogle Scholar
  14. 14.
    Sabuncu T, Vural H, Harma M (2001) Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 34(5):407–413CrossRefGoogle Scholar
  15. 15.
    Demir B, Cengiz H, Ungan I, Gedikbasi A, Karakoc G, Demir E et al (2015) The relationship between epicardial adipose tissue thickness and oxidative stress parameters in patients with isolated polycystic ovary syndrome. Gynecol Endocrinol 31(7):531–535PubMedGoogle Scholar
  16. 16.
    Zuo T, Zhu M, Xu W (2016) Roles of oxidative stress in polycystic ovary syndrome and cancers. Oxid Med Cell Longev 2016:8589318CrossRefGoogle Scholar
  17. 17.
    Kaya C, Erkan AF, Cengiz SD, Dunder I, Demirel OE, Bilgihan A (2009) Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular risk factors in patients with polycystic ovary syndrome. Fertil Steril 92(4):1372–1377CrossRefGoogle Scholar
  18. 18.
    Murri M, Luque-Ramirez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF (2013) Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update 19(3):268–288CrossRefGoogle Scholar
  19. 19.
    Milne GL, Dai Q, Roberts LJ 2nd (2015) The isoprostanes—25 years later. Biochim Biophys Acta 1851(4):433–445CrossRefGoogle Scholar
  20. 20.
    Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ 2nd (1990) A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 87(23):9383–9387CrossRefGoogle Scholar
  21. 21.
    Cracowski JL, Durand T, Bessard G (2002) Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci 23(8):360–366CrossRefGoogle Scholar
  22. 22.
    Halliwell B, Lee CY (2010) Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues. Antioxid Redox Signal 13(2):145–156CrossRefGoogle Scholar
  23. 23.
    Kromer BM, Tippins JR (1996) Coronary artery constriction by the isoprostane 8-epi prostaglandin F2 alpha. Br J Pharmacol 119(6):1276–1280CrossRefGoogle Scholar
  24. 24.
    Bauer J, Ripperger A, Frantz S, Ergun S, Schwedhelm E, Benndorf RA (2014) Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane-mediated thromboxane A2 receptor activation. Br J Pharmacol 171(13):3115–3131CrossRefGoogle Scholar
  25. 25.
    Seet RC, Lee CY, Chan BP, Sharma VK, Teoh HL, Venketasubramanian N et al (2011) Oxidative damage in ischemic stroke revealed using multiple biomarkers. Stroke 42(8):2326–2329CrossRefGoogle Scholar
  26. 26.
    Seet RC, Lee CY, Lim EC, Tan JJ, Quek AM, Chong WL et al (2010) Oxidative damage in Parkinson disease: measurement using accurate biomarkers. Free Radic Biol Med 48(4):560–566CrossRefGoogle Scholar
  27. 27.
    Caballero Balanza S, Martorell Aragones A, Cerda Mir JC, Belda Ramirez J, Navarro Ivanez R, Navarro Soriano A et al (2010) Leukotriene B4 and 8-isoprostane in exhaled breath condensate of children with episodic and persistent asthma. J Investig Allergol Clin Immunol 20(3):237–243PubMedGoogle Scholar
  28. 28.
    Kanaya AM, Wassel CL, Stoddard PJ, Harris TB, Cummings SR, Kritchevsky SB et al (2011) F2-isoprostanes and adiposity in older adults. Obesity (Silver Spring) 19(4):861–867CrossRefGoogle Scholar
  29. 29.
    Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81(1):19–25CrossRefGoogle Scholar
  30. 30.
    Pradelles P, Grassi J, Maclouf J (1985) Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. Anal Chem 57(7):1170–1173CrossRefGoogle Scholar
  31. 31.
    Kahn HS (2005) The “lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord 5:26CrossRefGoogle Scholar
  32. 32.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419CrossRefGoogle Scholar
  33. 33.
    Belli SH, Graffigna MN, Oneto A, Otero P, Schurman L, Levalle OA (2004) Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 81(3):624–629CrossRefGoogle Scholar
  34. 34.
    Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640–1645CrossRefGoogle Scholar
  35. 35.
    Banuls C, Rovira-Llopis S, Martinez de Maranon A, Veses S, Jover A, Gomez M et al (2017) Metabolic syndrome enhances endoplasmic reticulum, oxidative stress and leukocyte-endothelium interactions in PCOS. Metabolism 71:153–162CrossRefGoogle Scholar
  36. 36.
    Moti M, Amini L, Mirhoseini Ardakani SS, Kamalzadeh S, Masoomikarimi M, Jafarisani M (2015) Oxidative stress and anti-oxidant defense system in Iranian women with polycystic ovary syndrome. Iran J Reprod Med 13(6):373–378PubMedPubMedCentralGoogle Scholar
  37. 37.
    Ozer A, Bakacak M, Kiran H, Ercan O, Kostu B, Kanat-Pektas M et al (2016) Increased oxidative stress is associated with insulin resistance and infertility in polycystic ovary syndrome. Ginekol Pol 87(11):733–738CrossRefGoogle Scholar
  38. 38.
    Costa EC, Sa JC, Soares EM, Lemos TM, Maranhao TM, Azevedo GD (2010) Evaluation of cardiovascular risk by the LAP index in non-obese patients with polycystic ovary syndrome. Arq Bras Endocrinol Metabol 54(7):630–635CrossRefGoogle Scholar
  39. 39.
    Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK et al (2001) Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103(10):1410–1415CrossRefGoogle Scholar
  40. 40.
    Fenkci V, Fenkci S, Yilmazer M, Serteser M (2003) Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 80(1):123–127CrossRefGoogle Scholar
  41. 41.
    Nascimento JX, Chein MB, de Sousa RM, Ferreira Ados S, Navarro PA, Brito LM (2015) Importance of lipid accumulation product index as a marker of CVD risk in PCOS women. Lipids Health Dis 14:62CrossRefGoogle Scholar
  42. 42.
    Costabile G, Della Pepa G, Bozzetto L, Annuzzi G, Vetrani C, Giacco R et al (2015) Urine 8-isoprostane in relation to adiposity and insulin resistance in individuals at high cardiometabolic risk. Metab Syndr Relat Disord 13(4):187–191CrossRefGoogle Scholar
  43. 43.
    Ozegowska K, Pawelczyk L (2015) Cardiometabolic risk in patients with polycystic ovary syndrome. Ginekol Pol 86(11):840–848CrossRefGoogle Scholar
  44. 44.
    Berneis K, Rizzo M, Hersberger M, Rini GB, Di Fede G, Pepe I et al (2009) Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome. Int J Clin Pract 63(1):56–62CrossRefGoogle Scholar
  45. 45.
    Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98(8):731–733CrossRefGoogle Scholar
  46. 46.
    Ueland PM, Refsum H, Beresford SA, Vollset SE (2000) The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 72(2):324–332CrossRefGoogle Scholar
  47. 47.
    Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, Tyagi SC (2005) Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol 289(6):H2649–H2656CrossRefGoogle Scholar
  48. 48.
    Knekt P, Alfthan G, Aromaa A, Heliovaara M, Marniemi J, Rissanen H et al (2001) Homocysteine and major coronary events: a prospective population study amongst women. J Intern Med 249(5):461–465CrossRefGoogle Scholar
  49. 49.
    Badawy A, State O, El Gawad S, El Aziz OA (2007) Plasma homocysteine and polycystic ovary syndrome: the missed link. Eur J Obstet Gynecol Reprod Biol 131(1):68–72CrossRefGoogle Scholar
  50. 50.
    Makedos A, Goulis DG, Arvanitidou M, Mintziori G, Papanikolaou A, Makedou A et al (2011) Increased serum C-reactive protein levels in normal weight women with polycystic ovary syndrome. Hippokratia 15(4):323–326PubMedPubMedCentralGoogle Scholar
  51. 51.
    Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O et al (2004) Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 89(5):2160–2165CrossRefGoogle Scholar
  52. 52.
    Rosenfield RL (2001) Polycystic ovary syndrome and insulin-resistant hyperinsulinemia. J Am Acad Dermatol 45(3 Suppl):S95–S104CrossRefGoogle Scholar
  53. 53.
    Polak K, Czyzyk A, Simoncini T, Meczekalski B (2017) New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest 40(1):1–8CrossRefGoogle Scholar
  54. 54.
    Zhang R, Liu H, Bai H, Zhang Y, Liu Q, Guan L et al (2017) Oxidative stress status in Chinese women with different clinical phenotypes of polycystic ovary syndrome. Clin Endocrinol (Oxf) 86(1):88–96CrossRefGoogle Scholar
  55. 55.
    Gonzalez F, Nair KS, Daniels JK, Basal E, Schimke JM, Blair HE (2012) Hyperandrogenism sensitizes leukocytes to hyperglycemia to promote oxidative stress in lean reproductive-age women. J Clin Endocrinol Metab 97(8):2836–2843CrossRefGoogle Scholar
  56. 56.
    Pasquali R, Gambineri A (2018) New perspectives on the definition and management of polycystic ovary syndrome. J Endocrinol Invest. CrossRefPubMedGoogle Scholar
  57. 57.
    Condorelli RA, Calogero AE, Di Mauro M, Mongioi LM, Cannarella R, Rosta G et al (2018) Androgen excess and metabolic disorders in women with PCOS: beyond the body mass index. J Endocrinol Invest 41(4):383–388CrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2018

Authors and Affiliations

  • M. Calzada
    • 1
    Email author
  • N. López
    • 1
  • J. A. Noguera
    • 1
  • J. Mendiola
    • 2
  • A. M. Torres
    • 2
  1. 1.Clinical Analysis ServiceHospital University “Virgen de la Arrixaca”MurciaSpain
  2. 2.Division of Preventive Medicine and Public Health, Department of Health and Social SciencesUniversity of MurciaMurciaSpain

Personalised recommendations